Cosmos Health to Launch Patented Liver Fat Reduction Supplement Liv18 in Q2, Targeting Multi-Billion Dollar Market
COSM is trading near its 52-week low of $0.28 (6.4% above the low) on light trading volume (0.1× avg).
Summary
Cosmos Health announced the planned Q2 2026 U.S. launch of Liv18, a new patented supplement designed for liver fat reduction. This product, powered by BergacynFF®, has demonstrated clinical efficacy in two independent randomized controlled trials. For a micro-cap company, introducing a clinically proven and patented product into the multi-billion dollar U.S. liver health market, which addresses a condition affecting over 30% of adults, represents a material growth opportunity. This announcement follows a recent product-related news item on April 1st, indicating an active product development and expansion strategy. Investors will be watching for details on the Q2 launch and initial sales performance.
At the time of this announcement, COSM was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.2M. The 52-week trading range was $0.28 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.